drugset / Trial / NCT07281326
A Study of AK138D1 in Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I clinical trial testing the safety and effectiveness of AK138D1in patients with advanced cancer. The study will enroll up to 200 patients with various types of advanced solid tumors who haven't responded to standard treatments. Patients will receive AK138D1 to determine the safest dose and evaluate if the drug can help treat their cancer.
Timeline
- Start
- 2025-10-22
- Primary completion
- 2026-10-22
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK138D1 | Unknown | — | Intravenous |
Indications
No indication recorded.